The phase 3 PANOVA-3 trial, designed to evaluate concomitant treatment with tumor treating fields and chemotherapy, met its ...
Zenocutuzumab received accelerated approval from the FDA for the agent to treat non-small cell lung cancer (NSCLC) or ...
The FDA has granted fast track designation to LBS-007 for the treatment of patients with acute myeloid leukemia.
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...
Following a phase 1b trial, the potent and selective dual inhibitor of IRAK1 and IRAK4 received fast track designation for the treatment of patients with lower-risk myelodysplastic syndrome.
According to the American Lung Association, biomarker testing gaps and low screening rates continue to hinder lung cancer ...
Anito-Cel Shows 95% OS Rate in Relapsed/Refractory Myeloma ...
The FDA approved a companion diagnostic to identify patients with biliary tract cancer eligible for treatment with ...
Oncology nurses “play a pivotal role in guiding patients” through the genetic testing process, an expert explained.
Most patients with triple-negative breast cancer experienced a protocol-defined immune response with an investigational vaccine, phase 1 data showed. More than 70% of patients with triple-negative ...
Novel Drug Combo Is Promising for PD-L1-Resistant Solid Cancers ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback